Hepatitis B Vaccine (Recombinant)

Identification

Name
Hepatitis B Vaccine (Recombinant)
Accession Number
DB11627  (DB10308, DB10993)
Type
Biotech
Groups
Approved, Withdrawn
Biologic Classification
Vaccines
Inactivated / Recombinant
Description

Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, non-B hepatitis viruses. Hepatitis D virus, a defective virus requiring the “keeper function” of the hepatitis B virus, occurs either as a co-infection or super-infection in a HBsAg carrier.

Transmission of the virus occurs through percutaneous contact with contaminated blood, serum or plasma. Infection may also occur by the exposure of mucous surfaces, or intact or damaged skin to other body fluids such as saliva, mucosal secretions and semen.

There is no specific treatment for hepatitis. The incubation period may be as long as 6 months, followed by a very complex clinical course of an acute or chronic nature, often leading to hospitalization.

Viral hepatitis caused by hepatitis B virus is a major worldwide health problem, though the incidence and epidemiology vary widely among geographical areas and population subgroups.

In Canada, the United States and Northern Europe, 4% to 6% of the population are infected during their lifetime (mostly young adults); between 5% and 10% of infections lead to persistent viremia (carrier state). Certain population subgroups in these areas, however, are at high risk (see Indications and Clinical Use).

In Asia, infection often occurs early in life, leading to a hepatitis B marker prevalence of more than 70% in the general population and a carrier rate of up to 20%.

It is estimated that the reservoir of persistent hepatitis B surface antigen carriers amounts to 350 million people worldwide. Carriers are at a high risk of developing chronic liver disease which may lead to cirrhosis or primary hepatocellular carcinoma. A significant reduction in the incidence of hepatocellular carcinoma has been observed in children aged 6 to14 years following a nationwide hepatitis B vaccination in Taiwan. This resulted from a significant decline in the prevalence of hepatitis B antigen, the persistence of which is an essential factor in the development of hepatocellular carcinoma.

Vaccination against hepatitis B is expected in the long term to reduce the overall incidence of both hepatitis B and the chronic complications such as chronic active hepatitis and cirrhosis.

Synonyms
  • HBSAG
  • Hepatitis B antigen
  • Hepatitis B surface antigen
  • Hepatitis B Surface Antigen (rDNA)
  • Hepatitis B surface antigen (recombinant)
  • Hepatitis B surface antigen vaccine
  • Hepatitis B surface antigens
  • Hepatitis B Vaccine
  • Hepatitis B virus hbsag surface protein antigen
  • Hepatitis-B surface antigen
Product Ingredients
IngredientUNIICASInChI Key
Hepatitis B virus subtype ADW HBSAG surface protein antigenXL4HLC6JH6Not AvailableNot applicable
Hepatitis B virus subtype ADW2 HBSAG surface protein antigen9GCJ1L5D1P351186-51-1Not applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Engerix B Inj Sus 20mcg/mlSuspension20 mcgIntramuscularGlaxosmithkline Inc1991-12-31Not applicableCanada
Engerix-BInjection, suspension10 ug/.5mLIntramuscularA S Medication Solutions2007-04-252017-06-20Us
Engerix-BInjection, suspension20 ug/mLIntramuscularGlaxo Smith Kline Biologicals Sa2007-03-28Not applicableUs
Engerix-BInjection, suspension10 ug/.5mLIntramuscularGlaxo Smith Kline Biologicals Sa2007-04-25Not applicableUs
Engerix-BInjection, suspension20 ug/mLIntramuscularDispensing Solutions, Inc.2009-05-28Not applicableUs
Engerix-B (pediatric Dose)Suspension10 mcgIntramuscularGlaxosmithkline Inc2008-07-25Not applicableCanada
Heplisav-BInjection, solution20 ug/.5mLIntramuscularDynavax Technologies Corporation2018-01-01Not applicableUs
Recombivax HBInjection, suspension10 ug/mLIntramuscularRemedy Repack2014-02-202016-03-31Us
Recombivax HBInjection, suspension10 ug/mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1986-07-23Not applicableUs
Recombivax HBInjection, suspension10 ug/mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1986-07-23Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Engerix-BInjection, suspension20 ug/mLIntramuscularA S Medication Solutions2007-03-28Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ComvaxHepatitis B virus subtype ADW HBSAG surface protein antigen (5 ug/.5mL) + Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen (7.5 ug/.5mL)Injection, suspensionIntramuscularMerck Sharp & Dohme Limited1996-10-022016-11-18Us
PediarixHepatitis B virus subtype ADW2 HBSAG surface protein antigen (10 ug/.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 ug/.5mL) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (8 ug/.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 ug/.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (10 [iU]/.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (25 [iU]/.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [iU]/.5mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 [iU]/.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [iU]/.5mL)Injection, suspensionIntramuscularGlaxo Smith Kline Biologicals Sa2009-07-24Not applicableUs
TwinrixHepatitis B virus subtype ADW2 HBSAG surface protein antigen (20 ug/mL) + Hepatitis A virus strain HM175 antigen (formaldehyde inactivated) (720 [iU]/mL)Injection, suspensionIntramuscularA S Medication Solutions2007-06-072017-06-20Us
TwinrixHepatitis B virus subtype ADW2 HBSAG surface protein antigen (20 ug/mL) + Hepatitis A virus strain HM175 antigen (formaldehyde inactivated) (720 [iU]/mL)Injection, suspensionIntramuscularGlaxo Smith Kline Biologicals Sa2007-06-07Not applicableUs
TwinrixHepatitis B Vaccine (Recombinant) (20 mcg) + Hepatitis A Vaccine (720 unit)SuspensionIntramuscularGlaxosmithkline Inc1997-09-23Not applicableCanada
Twinrix JuniorHepatitis B Vaccine (Recombinant) (10 mcg) + Hepatitis A Vaccine (360 unit)SuspensionIntramuscularGlaxosmithkline Inc1998-11-06Not applicableCanada
Categories
UNII
IFJ010MNE4
CAS number
Not Available

Pharmacology

Indication

Active immunization against hepatitis B virus infection.

The vaccine will not protect against infection caused by hepatitis A and non-A non-B hepatitis viruses. As hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection or carrier state, it can be expected that hepatitis D will also be prevented by vaccination with hepatitis B virus vaccine.

The vaccine can be administered at any age from birth onwards. It may be used to start a primary course of vaccination or as a booster dose. It may also be used to complete a primary course of vaccination started with plasma-derived or yeast-derived vaccines or as a booster dose in subjects who have previously received a primary course of vaccination with plasma-derived or yeast-derived vaccines.

In areas of low prevalence of hepatitis B, vaccination is strongly recommended in subjects who are at increased risk of infection. These include the following groups:

  • Health professionals: physicians and surgeons; oral surgeons and dentists; nurses, dental nurses, dental hygienists, podiatrists; IV teams and operating room personnel; paramedical personnel in close contact with patients; staff in hemodialysis, nephrology, hepatology, hematology and oncology units; laboratory personnel handling blood and other clinical specimens; blood bank and plasma fractionation workers; pathologists and morgue attendants; cleaning staff who handle waste in hospitals; emergency and first aid workers; ambulance staff; dental, medical and nursing students.
  • Patients: patients receiving frequent blood transfusion or clotting factor concentrates, such as those in oncology units and those with thalassemia, sickle-cell anemia, cirrhosis, hemophilia, etc.; patients on hemodialysis; patients with type 2 diabetes.
  • Personnel and residents of institutions: persons with frequent and/or close contacts with high-risk groups; prisoners and prison staff; residents and staff of institutions for the developmentally challenged (those who are in contact with aggressive biting residents being at highest risk).
  • Persons at increased risk due to their sexual practices: males having sexual contact with other males; others with multiple sexual partners or with a recent history of sexually transmitted disease.
  • Persons who use injectable drugs illicitly.
  • Travellers to areas of high endemicity and their close contacts.
  • Household contacts of any of the above groups and of patients with acute or chronic hepatitis B infection.
  • Infants born of HBsAg-positive mothers.
  • Chronic Liver Disease (CLD): subjects with chronic liver disease; subjects at risk of developing CLD (e.g. Hepatitis C virus carriers, persons who abuse alcohol).
  • Others: police; fire fighters; armed forces personnel; morticians and embalmers; those who through their work or personal lifestyle may be exposed to the hepatitis B virus.
  • In areas of both low and high prevalence, vaccination should be offered to all young children and neonates at risk, as well as to adult high risk groups.
Structured Indications
Not Available
Pharmacodynamics

ENGERIX-B induces specific humoral antibodies against the surface antigen of hepatitis B virus (anti-HBs antibodies). An anti-HBs antibody titre above 10 IU/l correlates with protection to HBV infection.

Mechanism of action

ENGERIX®-B induces specific humoral antibodies against HBsAg (anti-HBs antibodies). It is generally accepted that an anti-HBs titre greater than 10 IU/L correlates with protection against hepatitis B virus infection. More than 90% of healthy adults, children and neonates developed protective anti-HBs titres one month after completing a primary vaccination schedule of ENGERIX®-B (hepatitis B vaccine (recombinant)).

Absorption

Vaccine is intended for intramuscular injection. Evaluation of pharmacokinetic properties is not required for vaccines.

Volume of distribution

Evaluation of pharmacokinetic properties is not required for vaccines.

Protein binding

Evaluation of pharmacokinetic properties is not required for vaccines.

Metabolism

Evaluation of pharmacokinetic properties is not required for vaccines.

Route of elimination

Evaluation of pharmacokinetic properties is not required for vaccines.

Half life

Evaluation of pharmacokinetic properties is not required for vaccines.

Clearance

Evaluation of pharmacokinetic properties is not required for vaccines.

Toxicity

Cases of overdose have been reported during post-marketing surveillance. Adverse events reported following overdosage were similar to those reported with normal vaccine administration.

Affected organisms
  • Hepatitis B virus
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Hepatitis B Vaccine (Recombinant).Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Hepatitis B Vaccine (Recombinant).Experimental, Illicit
2-MethoxyethanolThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with 2-Methoxyethanol.Experimental
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Hepatitis B Vaccine (Recombinant).Experimental, Illicit
AbataceptThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Abatacept.Approved
AbciximabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Abciximab.Approved
AbetimusThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Abetimus.Investigational
AbituzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Abituzumab.Investigational
ActeosideThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Acteoside.Investigational
AdalimumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Adalimumab.Approved
AdecatumumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Adecatumumab.Investigational
AdefovirThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Adefovir.Investigational
AducanumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Aducanumab.Investigational
AfelimomabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Afelimomab.Investigational
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Hepatitis B Vaccine (Recombinant).Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Hepatitis B Vaccine (Recombinant).Experimental, Investigational
AlefaceptThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alefacept.Approved, Investigational, Withdrawn
AlemtuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alemtuzumab.Approved, Investigational
AlicaforsenThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alicaforsen.Investigational
AlirocumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alirocumab.Approved
AmatuximabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Amatuximab.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Hepatitis B Vaccine (Recombinant).Approved
AMG 108The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with AMG 108.Investigational
AnakinraThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Anakinra.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Hepatitis B Vaccine (Recombinant).Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Hepatitis B Vaccine (Recombinant).Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Hepatitis B Vaccine (Recombinant).Investigational
AnifrolumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Anifrolumab.Investigational
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).Approved
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).Approved
ApolizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Apolizumab.Investigational
ApremilastThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Apremilast.Approved, Investigational
AscrinvacumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ascrinvacumab.Investigational
Asfotase AlfaThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Asfotase Alfa.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Hepatitis B Vaccine (Recombinant).Investigational
AtezolizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Atezolizumab.Approved
AVE9633The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with AVE9633.Investigational
AvelumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Avelumab.Approved
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Hepatitis B Vaccine (Recombinant).Approved
BapineuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bapineuzumab.Investigational
BasiliximabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Basiliximab.Approved, Investigational
BavituximabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bavituximab.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Hepatitis B Vaccine (Recombinant).Approved, Investigational
BectumomabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bectumomab.Investigational
BegelomabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Begelomab.Experimental, Investigational
BelataceptThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Belatacept.Approved
BelimumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Belimumab.Approved
BenznidazoleThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Benznidazole.Approved, Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Hepatitis B Vaccine (Recombinant).Approved, Vet Approved
BevacizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bevacizumab.Approved, Investigational
BIIB015The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with BIIB015.Investigational
BimagrumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bimagrumab.Investigational
bivatuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with bivatuzumab.Investigational
BlinatumomabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Blinatumomab.Approved
BlosozumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Blosozumab.Investigational
BococizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bococizumab.Investigational
Brentuximab vedotinThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Brentuximab vedotin.Approved
BriakinumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Briakinumab.Investigational
BrodalumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Brodalumab.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Hepatitis B Vaccine (Recombinant).Approved
BusulfanThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Busulfan.Approved, Investigational
CanakinumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Canakinumab.Approved, Investigational
CaplacizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Caplacizumab.Investigational
Capromab pendetideThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Capromab pendetide.Approved
CarlumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Carlumab.Investigational
CastanospermineThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Castanospermine.Experimental
CatumaxomabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Catumaxomab.Approved, Investigational, Withdrawn
Certolizumab pegolThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Certolizumab pegol.Approved
CetuximabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cetuximab.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Hepatitis B Vaccine (Recombinant).Approved, Investigational
CixutumumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cixutumumab.Investigational
CladribineThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cladribine.Approved, Investigational
ClazakizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Clazakizumab.Investigational
clenoliximabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with clenoliximab.Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Hepatitis B Vaccine (Recombinant).Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Hepatitis B Vaccine (Recombinant).Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Hepatitis B Vaccine (Recombinant).Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Hepatitis B Vaccine (Recombinant).Approved
Coltuximab ravtansineThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Coltuximab ravtansine.Investigational
ConatumumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Conatumumab.Investigational
ConcizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Concizumab.Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Hepatitis B Vaccine (Recombinant).Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Hepatitis B Vaccine (Recombinant).Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Hepatitis B Vaccine (Recombinant).Approved
CR002The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with CR002.Investigational
CrenezumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Crenezumab.Investigational
CrotedumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Crotedumab.Investigational
CyclophosphamideThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cyclophosphamide.Approved, Investigational
CyclosporineThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Hepatitis B Vaccine (Recombinant).Approved, Investigational
Cytomegalovirus immunoglobulinThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cytomegalovirus immunoglobulin.Approved, Experimental
DacetuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Dacetuzumab.Investigational
DaclizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Daclizumab.Approved, Investigational
DalotuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Dalotuzumab.Investigational
DaratumumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Daratumumab.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Hepatitis B Vaccine (Recombinant).Approved, Investigational
DemcizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Demcizumab.Investigational
DenosumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Denosumab.Approved
DeoxyspergualinThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Deoxyspergualin.Investigational
DepatuxizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Depatuxizumab.Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Hepatitis B Vaccine (Recombinant).Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Hepatitis B Vaccine (Recombinant).Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Hepatitis B Vaccine (Recombinant).Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Hepatitis B Vaccine (Recombinant).Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Hepatitis B Vaccine (Recombinant).Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Hepatitis B Vaccine (Recombinant).Vet Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Hepatitis B Vaccine (Recombinant).Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Hepatitis B Vaccine (Recombinant).Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Hepatitis B Vaccine (Recombinant).Approved
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Hepatitis B Vaccine (Recombinant).Approved, Investigational
DinutuximabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Dinutuximab.Approved
DoxifluridineThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Doxifluridine.Investigational
DulaglutideThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Dulaglutide.Approved
DuligotuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Duligotuzumab.Investigational
DupilumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Dupilumab.Approved, Investigational
DurvalumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Durvalumab.Approved
DusigitumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Dusigitumab.Investigational
EculizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Eculizumab.Approved, Investigational
EdrecolomabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Edrecolomab.Experimental, Investigational
EfalizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Efalizumab.Approved, Investigational
EldelumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Eldelumab.Investigational
ElotuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Elotuzumab.Approved
EmibetuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Emibetuzumab.Investigational
EmicizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Emicizumab.Approved, Investigational
EnokizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Enokizumab.Investigational
EpratuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Epratuzumab.Investigational
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Hepatitis B Vaccine (Recombinant).Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Hepatitis B Vaccine (Recombinant).Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Hepatitis B Vaccine (Recombinant).Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Hepatitis B Vaccine (Recombinant).Approved
EtanerceptThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Etanercept.Approved, Investigational
EtaracizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Etaracizumab.Investigational
EtrolizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Etrolizumab.Investigational
EverolimusThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Everolimus.Approved
EvolocumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Evolocumab.Approved
FarletuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Farletuzumab.Investigational
FiclatuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ficlatuzumab.Investigational
FigitumumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Figitumumab.Investigational
FingolimodThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Fingolimod.Approved, Investigational
FirategrastThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Firategrast.Investigational
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Hepatitis B Vaccine (Recombinant).Investigational
FludarabineThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Fludarabine.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Hepatitis B Vaccine (Recombinant).Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Hepatitis B Vaccine (Recombinant).Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Hepatitis B Vaccine (Recombinant).Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Hepatitis B Vaccine (Recombinant).Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Hepatitis B Vaccine (Recombinant).Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Hepatitis B Vaccine (Recombinant).Approved
FluorouracilThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Hepatitis B Vaccine (Recombinant).Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Hepatitis B Vaccine (Recombinant).Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Hepatitis B Vaccine (Recombinant).Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Hepatitis B Vaccine (Recombinant).Approved
FontolizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Fontolizumab.Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Hepatitis B Vaccine (Recombinant).Approved, Investigational, Withdrawn
FresolimumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Fresolimumab.Investigational
FulranumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Fulranumab.Investigational
GaliximabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Galiximab.Investigational
Gallium nitrateThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Gallium nitrate.Approved, Investigational
GanitumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ganitumab.Investigational
GantenerumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Gantenerumab.Investigational
GemcitabineThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Gemcitabine.Approved
Gemtuzumab ozogamicinThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Gemtuzumab ozogamicin.Approved
GevokizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Gevokizumab.Investigational
Glatiramer AcetateThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Glatiramer Acetate.Approved, Investigational
Glembatumumab vedotinThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Glembatumumab vedotin.Investigational
GlimepirideThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Glimepiride.Approved
GolimumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Golimumab.Approved
GS 0573The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with GS 0573.Investigational
GuselkumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Guselkumab.Approved
GusperimusThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Gusperimus.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Hepatitis B Vaccine (Recombinant).Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Hepatitis B Vaccine (Recombinant).Investigational
Human C1-esterase inhibitorThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Human C1-esterase inhibitor.Approved
Human Varicella-Zoster Immune GlobulinThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Human Varicella-Zoster Immune Globulin.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hepatitis B Vaccine (Recombinant).Approved, Vet Approved
HypericinThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Hypericin.Investigational
IbalizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ibalizumab.Investigational
Ibritumomab tiuxetanThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ibritumomab tiuxetan.Approved
IcatibantThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Icatibant.Approved
IdarucizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Idarucizumab.Approved
IGN311The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with IGN311.Investigational
IMC-1C11The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with IMC-1C11.Investigational
Immune Globulin HumanThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Immune Globulin Human.Approved, Investigational
InclacumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Inclacumab.Investigational
Indium In-111 satumomab pendetideThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Indium In-111 satumomab pendetide.Approved, Withdrawn
InebilizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Inebilizumab.Investigational
InfliximabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Infliximab.Approved
Inotuzumab ozogamicinThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Inotuzumab ozogamicin.Approved
IntetumumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Intetumumab.Investigational
IPH 2101The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with IPH 2101.Investigational
IpilimumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ipilimumab.Approved
IratumumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Iratumumab.Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Hepatitis B Vaccine (Recombinant).Investigational
IxekizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ixekizumab.Approved, Investigational
LabetuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Labetuzumab.Investigational
LampalizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lampalizumab.Investigational
LandogrozumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Landogrozumab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Hepatitis B Vaccine (Recombinant).Approved, Investigational
LenalidomideThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lenalidomide.Approved
LerdelimumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lerdelimumab.Investigational
LexatumumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lexatumumab.Investigational
LigelizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ligelizumab.Investigational
LisofyllineThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lisofylline.Investigational
Lorvotuzumab mertansineThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lorvotuzumab mertansine.Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Hepatitis B Vaccine (Recombinant).Approved
LucatumumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lucatumumab.Investigational
LumiliximabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lumiliximab.Investigational
MatuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Matuzumab.Investigational
MavrilimumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Mavrilimumab.Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Hepatitis B Vaccine (Recombinant).Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Hepatitis B Vaccine (Recombinant).Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Hepatitis B Vaccine (Recombinant).Vet Approved
MelphalanThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Melphalan.Approved
MepolizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Mepolizumab.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Hepatitis B Vaccine (Recombinant).Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Hepatitis B Vaccine (Recombinant).Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Hepatitis B Vaccine (Recombinant).Approved, Vet Approved
MilatuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Milatuzumab.Investigational
Mirvetuximab SoravtansineThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Mirvetuximab Soravtansine.Investigational
MizoribineThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Mizoribine.Investigational
MogamulizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Mogamulizumab.Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Hepatitis B Vaccine (Recombinant).Approved, Vet Approved
MotavizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Motavizumab.Investigational
MuromonabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Muromonab.Approved, Investigational
Mycophenolate mofetilThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Mycophenolic acid.Approved
MYO-029The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with MYO-029.Investigational
NafamostatThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Nafamostat.Approved, Investigational
Naptumomab EstafenatoxThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Naptumomab Estafenatox.Investigational
NatalizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Hepatitis B Vaccine (Recombinant).Investigational
NebacumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Nebacumab.Experimental
NecitumumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Necitumumab.Approved
NimotuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Nimotuzumab.Investigational
NivolumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Nivolumab.Approved
ObiltoxaximabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Obiltoxaximab.Approved
ObinutuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Obinutuzumab.Approved
OcrelizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ocrelizumab.Approved, Investigational
OfatumumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ofatumumab.Approved
OlaratumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Olaratumab.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Hepatitis B Vaccine (Recombinant).Investigational
OlokizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Olokizumab.Investigational
OmalizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Omalizumab.Approved, Investigational
OnartuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Onartuzumab.Investigational
OregovomabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Oregovomab.Investigational
OtelixizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Otelixizumab.Investigational
OzanezumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ozanezumab.Investigational
PalivizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Palivizumab.Approved, Investigational
PanitumumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Panitumumab.Approved, Investigational
PaquinimodThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Paquinimod.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Hepatitis B Vaccine (Recombinant).Approved
PatritumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Patritumab.Investigational
PembrolizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pembrolizumab.Approved
PertuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pertuzumab.Approved
PexelizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pexelizumab.Investigational
PimecrolimusThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PirarubicinThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pirarubicin.Investigational
PirfenidoneThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pirfenidone.Approved, Investigational
Polatuzumab VedotinThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Polatuzumab Vedotin.Investigational
PomalidomideThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pomalidomide.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Hepatitis B Vaccine (Recombinant).Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Hepatitis B Vaccine (Recombinant).Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Hepatitis B Vaccine (Recombinant).Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Hepatitis B Vaccine (Recombinant).Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Hepatitis B Vaccine (Recombinant).Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Hepatitis B Vaccine (Recombinant).Experimental, Investigational
PRO 140The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with PRO 140.Investigational
PRO-542The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with PRO-542.Investigational
R1507The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with R1507.Investigational
RacotumomabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Racotumomab.Investigational
RamucirumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ramucirumab.Approved, Investigational
RanibizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ranibizumab.Approved
RaxibacumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Raxibacumab.Approved
ReslizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Reslizumab.Approved, Investigational
RI 624The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with RI 624.Investigational
RIGScan CR49The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with RIGScan CR49.Investigational
RilonaceptThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Rilonacept.Approved
RilotumumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Rilotumumab.Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Hepatitis B Vaccine (Recombinant).Approved
RituximabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Rituximab.Approved
RobatumumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Robatumumab.Investigational
RomosozumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Romosozumab.Investigational
RontalizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Rontalizumab.Investigational
Sacituzumab govitecanThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Sacituzumab govitecan.Investigational
SarilumabThe risk or severity of infection can be increased when Sarilumab is combined with Hepatitis B Vaccine (Recombinant).Approved
SecukinumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Secukinumab.Approved
SemapimodThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Semapimod.Investigational
SeocalcitolThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Seocalcitol.Experimental, Investigational
SeribantumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Seribantumab.Investigational
SibrotuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Sibrotuzumab.Investigational
SiltuximabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Siltuximab.Approved
SiplizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Siplizumab.Investigational
SirolimusThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Sirolimus.Approved, Investigational
SirukumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Sirukumab.Investigational
SolanezumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Solanezumab.Investigational
SteproninThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Stepronin.Approved
SYM001The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with SYM001.Investigational
TabalumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tabalumab.Investigational
TacrolimusThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tacrolimus.Approved, Investigational
TanezumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tanezumab.Investigational
TarextumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tarextumab.Investigational
TB-402The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with TB-402.Investigational
Technetium Tc-99m arcitumomabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Technetium Tc-99m arcitumomab.Approved, Investigational
TeplizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Teplizumab.Investigational
TepoxalinThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tepoxalin.Vet Approved
TeriflunomideThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Teriflunomide.Approved
Tetanus Immune GlobulinThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tetanus Immune Globulin.Approved
ThalidomideThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Thalidomide.Approved, Investigational, Withdrawn
ThiotepaThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Thiotepa.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
TNX-901The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with TNX-901.Investigational
TocilizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tocilizumab.Approved
TofacitinibThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tofacitinib.Approved, Investigational
TositumomabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tositumomab.Approved, Investigational
TovetumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tovetumab.Investigational
TralokinumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tralokinumab.Investigational
TrastuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Trastuzumab emtansine.Approved
TRC105The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with TRC105.Investigational
TremelimumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tremelimumab.Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Hepatitis B Vaccine (Recombinant).Approved, Vet Approved
TriptolideThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Triptolide.Investigational
TrofosfamideThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Trofosfamide.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Hepatitis B Vaccine (Recombinant).Approved
UstekinumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ustekinumab.Approved, Investigational
VedolizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Vedolizumab.Approved
VeltuzumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Veltuzumab.Investigational
VisilizumabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Visilizumab.Investigational
VoclosporinThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Voclosporin.Investigational
VolociximabThe therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Volociximab.Investigational
XmAb 2513The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with XmAb 2513.Investigational
XTL-001The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with XTL-001.Investigational
Food Interactions
Not Available

References

General References
  1. Engerix-B Monograph [Link]
External Links
PubChem Substance
347911220
Drugs.com
Drugs.com Drug Page
Wikipedia
Hepatitis_B_vaccine
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingPreventionHealthy Volunteers1
1CompletedPreventionDiseases Caused by Streptococcus Pneumoniae and Nontypable Haemophilus Influenzae / Haemophilus Influenzae-Streptococcus Pneumoniae Vaccine1
1CompletedPreventionHookworm Disease / Hookworm Infection1
1CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
1CompletedPreventionInflammatory Bowel Diseases (IBD)1
1CompletedPreventionViral Hepatitis B3
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1RecruitingPreventionExposure to Hepatitis B Virus1
1RecruitingPreventionHookworm Disease / Hookworm Infection1
1Unknown StatusPreventionHuman Immunodeficiency Virus (HIV) Infections1
1Unknown StatusPreventionPlasmodium Infections2
1Unknown StatusTreatmentChronic Hepatitis B Infection1
2CompletedPreventionBacterial Infections; Virus Diseases1
2CompletedPreventionCervical Cancers / Cervical Intraepithelial Neoplasia (CIN)1
2CompletedPreventionDiphtheria / Haemophilus Influenzae Type b (Hib) / Pertussis / Poliomyelitis / Tetanus / Viral Hepatitis B1
2CompletedPreventionDiphtheria / Pertussis / Poliomyelitis / Tetanus / Viral Hepatitis B1
2CompletedPreventionHepatocellular,Carcinoma / Viral Hepatitis B1
2CompletedPreventionMeningitis / Meningococcal Infections1
2CompletedPreventionPlasmodium Infections4
2CompletedPreventionPrevention of Meningococcal Disease1
2CompletedPreventionViral Hepatitis B8
2CompletedTreatmentBipolar Disorder (BD) / Depression / Human Immunodeficiency Virus (HIV) Infections / Schizoaffective Disorders / Schizophrenic Disorders / Substance Abuse1
2TerminatedTreatmentBladder Cancers / Cancer, Breast / Malignant Neoplasm of Colon1
3Active Not RecruitingPreventionHepatitis E1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionChronic Kidney Disease (CKD)1
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B Infection / Pertussis / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionDiphtheria / Pertussis / Poliomyelitis / Viral Hepatitis B1
3CompletedPreventionEnd Stage Renal Disease (ESRD)1
3CompletedPreventionHaemophilus Influenzae Infections / Pneumococcal Diseases / Streptococcal Infections / Streptococcus Pneumoniae1
3CompletedPreventionHaemophilus Influenzae Type B1
3CompletedPreventionHaemophilus Influenzae Type B / Haemophilus Influenzae Type b Diseases / Meningococcal Serogroup C Diseases / Neisseria Meningitidis1
3CompletedPreventionHealthy Volunteers2
3CompletedPreventionHealthy Volunteers / Infants / Viral Hepatitis B1
3CompletedPreventionHepatitis B Virus Infection1
3CompletedPreventionPneumonia & AOM Caused by S. Pneumoniae & H. Influenzae / Streptococcal Infections1
3CompletedPreventionStreptococcal Infections1
3CompletedPreventionViral Hepatitis B21
3CompletedPreventionViral Hepatitis B / Virus Diseases1
3Not Yet RecruitingPreventionVenereal Warts1
4Active Not RecruitingPreventionHIV/AIDS and Infections1
4CompletedNot AvailableHepatitis1
4CompletedNot AvailableProphylaxis Hepatitis B / Viral Hepatitis B1
4CompletedBasic ScienceViral Hepatitis B1
4CompletedPreventionHepatitis1
4CompletedPreventionHepatitis A / Viral Hepatitis B4
4CompletedPreventionHepatitis A / Viral Hepatitis B / Viral Hepatitis Vaccines1
4CompletedPreventionHepatitis B Vaccine1
4CompletedPreventionHepatitis B Vaccine / Viral Hepatitis B1
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Viral Hepatitis B1
4CompletedPreventionImmune Response / Seroprevalence / Viral Hepatitis B1
4CompletedPreventionPapillomavirus Infections1
4CompletedPreventionPeritoneal dialysis therapy / Renal Disease, End-Stage1
4CompletedPreventionVaccination / Viral Hepatitis B1
4CompletedPreventionViral Hepatitis B9
4CompletedTreatmentHepatitis B,Chronic1
4Enrolling by InvitationTreatmentChronic Hepatitis B Infection1
4RecruitingBasic ScienceHepatitis C Infection1
4RecruitingBasic ScienceImmunization; Infection / Viral Hepatitis B1
4TerminatedPreventionHuman Papillomavirus Infections1
4Unknown StatusPreventionHealthy Volunteers1
4Unknown StatusPreventionViral Hepatitis B3
Not AvailableActive Not RecruitingBasic ScienceViral Hepatitis B1
Not AvailableCompletedNot AvailableChronic Kidney Disease (CKD)1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedBasic ScienceInnate Immune Response1
Not AvailableCompletedPreventionChronic Hepatitis C Infection / Hepatitis A / Medication Adherence / Risk Behaviors / Substance Abuse, Intravenous / Viral Hepatitis B1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Infections, Pneumococcal / Pertussis / Rubeola / Viral Hepatitis B1
Not AvailableCompletedPreventionVaccination; Complications, Reaction, Serum1
Not AvailableCompletedPreventionViral Hepatitis B1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
Not AvailableRecruitingNot AvailableInflammatory Bowel Diseases (IBD)1
Not AvailableRecruitingBasic ScienceNewborn Vaccine Immunogenicity1
Not AvailableTerminatedTreatmentGluten Enteropathy1
Not AvailableUnknown StatusPreventionInflammatory Bowel Diseases (IBD)1
Not AvailableUnknown StatusPreventionVaccines / Viral Hepatitis B1
Not AvailableWithdrawnPreventionHealthy, no Evidence of Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, suspensionIntramuscular
SuspensionIntramuscular20 mcg
Injection, suspensionIntramuscular10 ug/.5mL
Injection, suspensionIntramuscular20 ug/mL
SuspensionIntramuscular10 mcg
Injection, solutionIntramuscular20 ug/.5mL
Injection, suspensionIntramuscular10 ug/mL
Injection, suspensionIntramuscular; Subcutaneous10 ug/mL
Injection, suspensionIntramuscular; Subcutaneous40 ug/mL
Injection, suspensionIntramuscular; Subcutaneous5 ug/.5mL
SolutionIntramuscular40 mcg
SolutionIntramuscular10 mcg
SuspensionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on October 17, 2016 15:25 / Updated on January 14, 2018 10:04